Here, we describe a study in which we have examined the effects of an additional aromatic ring on the potency of DPEITC and its ability to selectively target mutant p53, alone and in combination with chemotherapeutic drugs (topoisomerase inhibitors), in breast cancer, including human epidermal growth factor receptor 2 (Her-2/neu) (HER2+), Luminal A, and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to breast carcinoma.